Highly malignant intra-hepatic metastatic hepatocellular carcinoma in rats

American Journal of Translational Research

Volumn 3, Issue 1, 2011, Pages 114-120

  Guo, Yang ^a   Klein, Rachel ^a   Omary, Reed A ^a,b   Yang, Guang Yu ^a   Larson, Andrew C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

Hepatocellular carcinoma (HCC); Histopathology; McARH7777 rat HCC cell line; MRI; N1 s1 rat HCC cell line; Orthotopic implantation; Rodent model

Indexed keywords

CD34 ANTIGEN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BUFFALO RAT; CANCER MODEL; CANCER RECURRENCE; CANCER TRANSPLANTATION; FEMALE; LIVER CELL CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; SPRAGUE DAWLEY RAT; STAINING; TUMOR GROWTH; TUMOR VOLUME;

RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 78650205375     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Thomas MB and Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899.
3. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
4. Maggard M, Meng L, Ke B, Allen R, Devgan L and Imagawa DK. Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann Surg Oncol 2001; 8: 32-37.
5. Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T, Arihiro K, Okajima M and Asahara T. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 2007; 7: 347-355.
6. Schmitz V, Barajas M, Wang L, Peng D, Duarte M, Prieto J and Qian C. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 2001; 34: 72-81.
7. Novikoff AB. A transplantable rat liver tumor induced by 4-dimethylaminoazobenzene. Cancer Res 1957; 17: 1010-1027.
8. Jaroszeski MJ, Coppola D, Pottinger C, Benson K, Gilbert RA and Heller R. Treatment of hepatocellular carcinoma in a rat model using electrochemotherapy. Eur J Cancer 2001; 37: 422-430.
9. Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT and Ting G. Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma. J Nucl Med 1996; 37: 332-335.
10. Garin E, Denizot B, Roux J, Noiret N, Lepareur N, Moreau M, Mesba H, Laurent JF, Herry JY, Bourguet P, Benoit JP and Lejeune JJ. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat. Lab Anim 2005; 39: 314-320.
11. Ju S, McLennan G, Bennett SL, Liang Y, Bonnac L, Pankiewicz KW and Jayaram HN. Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers. J Vasc Interv Radiol 2009; 20: 410-414.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Quaglia A, Jutand MA, Dhillon A, Godfrey A, Togni R, Bioulac-Sage P, Balabaud C, Winnock M and Dhillon AP. Classification tool for the systematic histological assessment of hepatocellular carcinoma, macroregenerative nodules, and dysplastic nodules in cirrhotic liver. World J Gastroenterol 2005; 11: 6262-6268.
14. Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y, Graeme-Cook F, Yamabe H, Ikai I, Cleary KR, Fujita S, Flejou JF, Zukerberg LR, Nagorney DM, Belghiti J, Yamaoka Y and Vauthey JN. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002; 26: 25-34.
15. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995; 22: 983-993.
16. Fox SB and Harris AL. Histological quantitation of tumour angiogenesis. Apmis 2004; 112: 413-430.
17. Kishi K, Shikata T, Hirohashi S, Hasegawa H, Yamazaki S and Makuuchi M. Hepatocellular carcinoma. A clinical and pathologic analysis of 57 hepatectomy cases. Cancer 1983; 51: 542-548.
18. Matsumoto Y, Fujii H, Matsuda M and Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg 2001; 8: 435-440.
19. Akihiro Toyosaka EO, Masao Mitsunobu, Takeshi Oriyama, Norio Nakao, Koui Miura. Intrahepatic Metastases in Hepatocellular Carcinoma: Evidence for Spread Via the Portal Vein as an Efferent Vessel. American Journal of Gastroenterology 1996; 91: 1610-1615.
20. Kramer MG. Evaluation of hepatocellular carcinoma models for preclinical studies. Drug Discovery Today: Disease Models (Cancer) 2005; 2: 41-49.